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Prion	amyloidosis	occurred	 in	 the	heart	 of	 1	of	 3	ma-
caques	 intraperitoneally	 inoculated	with	 bovine	 spongiform	
encephalopathy	 prions.	 This	 macaque	 had	 a	 remarkably	
long duration of disease and signs of cardiac distress. Variant 
Creutzfeldt-Jakob	disease,	caused	by	transmission	of	bovine	
spongiform encephalopathy to humans, may manifest with 
cardiac symptoms from prion-amyloid cardiomyopathy.
Human prion diseases are progressive neurologic dis-orders that include sporadic, genetic, and acquired 
forms of Creutzfeldt-Jakob disease (CJD) (1). A key step in 
disease initiation is conversion of PrPC into PrPSc, which is 
partially resistant to proteolytic digestion and an essential 
part of prion infectivity. Transmission of bovine spongi-
form encephalopathy (BSE) to humans has led to a novel 
form of acquired CJD, termed variant CJD (vCJD) (2). The 
pathogenesis of vCJD differs substantially from sporadic 
CJD with remarkable colonization of non–central nervous 
system regions with infectious prions and PrPSc (3).
Although risk reduction measures have been intro-
duced to limit transmission from BSE-diseased cattle to 
humans, vCJD has occurred in several hundred instances 
(www.eurocjd.ed.ac.uk). Most clinically affected vCJD 
patients are homozygous for methionine on polymorphic 
codon 129 on the gene coding PrP (PRNP), and the clini-
cal presentation of vCJD in these patients is uniform (4). 
The occurrence of atypical clinical features in persons with 
vCJD that encodes methionine and valine on PRNP codon 
129 and human-to-human transmission of vCJD through 
blood transfusion have raised concern about atypical clini-
cal features and alternative distribution of PrPSc in vCJD 
(5). We report on the novel clinicopathologic characteris-
tics of vCJD as prion-amyloid cardiomyopathy in 1 of 3 
macaques inoculated with BSE.
The Study
In 2002, three rhesus macaques were inoculated with 
BSE intraperitoneally (10 mL of a 10% homogenate of 
brain from BSE-diseased cattle). As controls, 2 rhesus ma-
caques received saline (10 mL) and 1 was untreated. All 
procedures involving rhesus macaques were performed at 
the Institute of Neuropathology, University Medical Center 
Hamburg-Eppendorf (Hamburg, Germany), in accordance 
with the German Animal Welfare Act and the Council Di-
rective 86/609/EEC (Permit 33.42502/08–08.02 LAVES, 
Lower Saxony, Germany). Animals were observed for 
clinical signs of prion disease and, when signs of terminal 
prion disease became evident, were euthanized and under-
went autopsy. In all 3 BSE-challenged macaques and none 
of the controls a progressive neurologic disease developed 
49, 59, and 61 months postinoculation. Examination of 
brain by using hematoxylin and eosin staining showed typi-
cal neuropathologic features of vCJD (data not shown) and 
abundant deposits of PrPSc in the cortex, basal ganglia, and 
cerebellum in paraffin-embedded tissue blots performed as 
described by using 12F10 monclonal antiprion antibody 
(6) (Figure 1, panel A). The mobility of the unglycosyl-
ated PrPSc band and the glycoform ratio of proteinase K–
digested PrPSc were similar to those in BSE when assessed 
by Western blot analysis by using monoclonal POM-1 anti-
prion antibody as described (7) (Figure 1, panel B).
Besides lymphoreticular tissues, the muscular compart-
ment is targeted by prions (7,8). Thus, we assessed presence 
of PrPSc in skeletal and heart muscle by Western blot analysis 
with sodium phosphotungstic acid precipitation for enrich-
ment of PrPSc and protein misfolding cyclic amplification by 
using published protocols (3). We could not detect substan-
tial amounts of PrPSc in skeletal muscle (Figure 2, panel A). 
One macaque showed abundant PrPSc (≈1/100 of PrPSc found 
in brain) in heart in Western blot and protein misfolding cy-
clic amplification (Figure 2, panels A, B). Paraffin-embedded 
tissue blot analysis of this heart showed PrPSc as amyloid, oc-
cupying considerable stretches of heart tissue, mainly in the 
septum (Figure 2, panel C), whereas no PrPSc could be seen 
in hearts of other macaques (data not shown). These findings 
were confirmed by strong Congo red–positive patch-like de-
positions in cardiomyocytes in the heart of this monkey (Fig-
ure 2, panel D). The primate with cardiac PrPSc showed the 
longest disease duration (4 months, compared with 4 weeks 
for other BSE-infected monkeys), signs of cardiac affection 
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when assessed by relevant makers of cardiac hypertrophy 
and of cardiac distress–associated inflammation, and only 
this macaque showed clinical signs of fatigue and signs of 
cardiac distress (i.e., venous congestion) on autopsy (Table, 
online Technical Appendix Table, wwwnc.cdc.gov/EID/
article/19/6/12-0906-Techapp1.pdf). Histologic examination 
of heart tissue with hematoxylin and eosin staining and im-
munohistochemical stainings against B and T cells (CD20 
[not shown] and CD3) did not provide evidence for toxic car-
diomyopathy (i.e., fibrosis or vacuolization), nor did we find 
signs of inflammatory reaction (Figure 2, panel D).
Conclusions
Although the vCJD epidemic is declining, considerable 
concern exists that clinical characterastics of vCJD will shift. 
The most important genetic risk factor for development of 
vCJD is homozygosity for methionine on PRNP codon 129, 
and all but 1 patient with clinical vCJD carry this polymor-
phism (5). Thus, future cases of vCJD with longer incubation 
times are likely to comprise more patients with alternative 
codon 129 polymorphisms than methionine homozygosity. 
Data from rodent experiments indicate that clinical features 
of vCJD may differ in these patients (9). Thus, the next de-
cades may see a shift in vCJD phenotypes. Further uncertain-
ty for atypical cases in humans results from the possibility 
of secondary transmission of vCJD through blood products 
from subclinical carriers, which may lead to development of 
nonclassical vCJD phenotypes (5).
We showed that BSE infection of primates may occur 
as prion-amyloid cardiomyopathy. Because prion-amyloid 
cardiomyopathy developed in only 1 of 3 macaques, host-
encoded factors, such as genetic makeup, probably influ-
ence development of this cardiac phenotype. All macaques 
are homozygous for methionine on PRNP codon 129; thus, 
prion-amyloid cardiomyopathy cannot be related to poly-
morphic codon 129 in our study (10). Cardiac involvement 
has been observed in a patient with sporadic CJD and is 
prominent in prion-diseased mice expressing PrPC lacking 
its membrane anchor (11,12). We considered the possibil-
ity that preexisting pathology, such as spontaneous cardio-
myopathy or inflammation of the heart, might have contrib-
uted to cardiac PrPSc, and the fact that we did not find any 
evidence for toxic cardiomyopathy or inflammation in the 
primate does not exclude this possibility. Because the ma-
caque with abundant PrPSc deposition in heart had longer 
disease duration, it is also possible that longer disease du-
ration, which favors centrifugal spread of prions to periph-
eral tissues, contributed to cardiac affection in this primate 
(7). Peripheral deposition of PrPSc in vCJD is well stud-
ied (3). We were surprised by the amount and deposition 
type of PrPSc in heart, reaching 1/100 of the amount seen 
in brain and deposited as amyloid across large stretches of 
heart tissue. Skeletal muscle of prion-diseased patients and 
nonhuman primates routinely harbor minimal amounts of 
PrPSc (<1/1000 that found in brain), and PrPSc in muscle is 
virtually impossible to detect by in situ methods (6,8,13). 
To our knowledge, PrPSc has not been detected in heart of 
vCJD-diseased persons or in patients with systemic amy-
loidosis, although primates orally exposed to BSE show 
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Table.	Characteristics	of	3	rhesus	macaques	in	study	of	BSE-associated prion-amyloid cardiomyopathy* 
Primate Age at inoculation 
Time to clinical 
disease, mo 
Disease 
duration, wk Cardiac PrPSc 
Signs of cardiac distress 
at autopsy 
BSE inoculated 8 y 49 4 Neg Neg 
 5	y 59 18 Pos Pos 
 1 y 61 4 Neg Neg 
Control 8 mo NA NA Neg Neg 
 17 y NA NA Neg Neg 
 19 y NA NA Neg Neg 
*BSE,	bovine	spongiform	encephalopathy;	Neg,	negative;	Pos,	positive;	NA,	not	applicable. 
 
Figure	1.	PrPSc	distribution	and	content	in	brain	of	bovine	spongiform	
encephalopathy	 (BSE)–infected	 rhesus	 macaques.	 A)	 Paraffin-
embedded	 tissue	blot	 of	 striatum	and	 cerebellum	show	a	 typical	
BSE-like deposition pattern of PrPSc	with	no	differences	between	
individual	 BSE-diseased	 monkeys	 at	 49,	 59,	 and	 61	 months	
postinoculation	(mpi).	Scale	bars	=	1	mm.	B)	Western	blot	analysis	
for PrPSc	in	brain	of	BSE-infected	monkeys	with	incubation	times	of	
49,	59,	and	61	mpi.	PrPSc-type	is	as	expected	for	BSE	prions,	and	
no major differences in PrPSc load were detected. All samples were 
proteinase	K–digested;	loading	amount	was	0.5	and	0.1	mg	fresh	
wet tissue for each sample 
Prion-Amyloid Cardiomyopathy
very low amounts of cardiac PrPSc (8,14,15). The lack of 
cardiac PrPSc in vCJD may result from small cohorts inves-
tigated. Because the spectrum of vCJD is likely to change, 
broad application of current clinical criteria for vCJD in 
clinical practice may lead to underreporting of vCJD, miss-
ing atypical cases of vCJD.
In conclusion, we showed that BSE-infection of 
primates may lead to prion-amyloid cardiomyopathy. 
These data should be considered when vCJD surveillance 
is conducted.
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etymologia
From the Greek halios (marine) and ōtos (ear), abalo-nes, genus Haliotis, were first mentioned ≈2,500 years 
ago by Aristotle, who wrote of “the wild limpet (called by 
some the ‘sea ear’).” In D’Arcy Thompson’s translation 
of Aristotle, he notes that “wild limpet” is “commonly 
attributed to Fissurella graecea ... and conceals a forgot-
ten name for Haliotis.” The “sea ear” was familiar to the 
Greeks and was named otia (little ear) by Pliny.
Shewanella haliotis, a species of rod-shaped, gram-
negative, facultatively anaerobic bacteria, was first iso-
lated from the gut microflora of abalones collected from 
the ocean near Yeosu, South Korea, by Kim et al. in 
2007. The genus Shewanella had been previously named 
in 1985 by MacDonell and Colwell in honor of Scottish 
microbiologist James M. Shewan, for his work in fisheries 
microbiology.
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Shewanella haliotis 
[shooʺə-nelʹə hāʺlĭ-oʹtĭs]
